Mariska Bot1, Ingeborg A Brouwer2, Miquel Roca3, Elisabeth Kohls4, Brenda W J H Penninx1, Ed Watkins5, Gerard van Grootheest1, Mieke Cabout2, Ulrich Hegerl4, Margalida Gili3, Matthew Owens5, Marjolein Visser2. 1. Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health research institute, GGZ inGeest Specialized Mental Health Care, Amsterdam, the Netherlands. 2. Department of Health Sciences, Faculty of Science and Amsterdam Public Health research institute, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. 3. Institut Universitari d' Investigació en Ciències de la Salut, Idisba, Rediapp, University of Balearic Islands, Palma de Mallorca, Spain. 4. Department of Psychiatry and Psychotherapy, University Leipzig, Medical Faculty, Leipzig, Germany. 5. Department of Psychology, University of Exeter, Exeter, United Kingdom.
Abstract
Importance: Effects of nutritional interventions on the prevention of major depressive disorder (MDD) in overweight adults are unknown. Objective: To examine the effect of 2 nutritional strategies (multinutrient supplementation, food-related behavioral activation therapy) and their combination for prevention of a new MDD episode in overweight adults with subsyndromal depressive symptoms. Design, Setting, and Participants: This multicenter 2 × 2 factorial randomized clinical trial included overweight adults (body mass index, 25-40) with elevated depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] scores ≥5) and no MDD episode in the past 6 months from 4 European countries. A total of 1025 adults were randomized (July 30, 2015-October 12, 2016) and followed up for 1 year (October 13, 2017). Interventions: Daily multinutrient supplements (1412-mg omega-3 fatty acids, 30-μg selenium, 400-μg folic acid, and 20-μg vitamin D3 plus 100-mg calcium) vs placebo and 21 individual or group therapy sessions vs none (blinded to researchers) for 1 year. Participants were allocated to placebo without therapy (n = 257), placebo with therapy (n = 256), supplements without therapy (n = 256), and supplements with therapy (n = 256). Main Outcome and Measures: Cumulative 1-year onset of MDD via the Mini International Neuropsychiatric Interview at 3, 6, and 12 months. Logistic regression using effect-coded variables (-1 indicating control, 1 indicating intervention) evaluated intervention effects both individually and in combination (interaction) on MDD onset. Results: Among 1025 participants (mean age, 46.5 years; 772 women [75%]; mean BMI, 31.4), 779 (76%) completed the trial. During the 12-month follow-up, 105 (10%) developed MDD: 25 (9.7%) patients in the placebo without therapy, 26 (10.2%) in the placebo with therapy, 32 (12.5%) in the supplement without therapy, and 22 (8.6%) in the supplement with therapy group. None of the treatment strategies affected MDD onset. The odds ratio (OR) for supplements was 1.06 (95% CI, 0.87-1.29); for therapy, 0.93 (95% CI, 0.76-1.13); and for their combination, 0.93 (95% CI, 0.76-1.14; P for interaction, .48). One person in the supplementation with therapy group, died. Twenty-four patients in each of the placebogroups and 24 patients in the supplementation with therapy group were hospitalized, and 26 patients in the supplementation-only group were hospitalized. Conclusions and Relevance: Among overweight or obese adults with subsyndromal depressive symptoms, multinutrient supplementation compared with placebo and food-related behavioral activation therapy compared with no therapy did not reduce episodes of major depressive disorder during 1 year. These findings do not support the use of these interventions for prevention of major depressive disorder. Trial registration: ClinicalTrials.gov Identifier: NCT02529423.
RCT Entities:
Importance: Effects of nutritional interventions on the prevention of major depressive disorder (MDD) in overweight adults are unknown. Objective: To examine the effect of 2 nutritional strategies (multinutrient supplementation, food-related behavioral activation therapy) and their combination for prevention of a new MDD episode in overweight adults with subsyndromal depressive symptoms. Design, Setting, and Participants: This multicenter 2 × 2 factorial randomized clinical trial included overweight adults (body mass index, 25-40) with elevated depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] scores ≥5) and no MDD episode in the past 6 months from 4 European countries. A total of 1025 adults were randomized (July 30, 2015-October 12, 2016) and followed up for 1 year (October 13, 2017). Interventions: Daily multinutrient supplements (1412-mg omega-3 fatty acids, 30-μg selenium, 400-μg folic acid, and 20-μg vitamin D3 plus 100-mg calcium) vs placebo and 21 individual or group therapy sessions vs none (blinded to researchers) for 1 year. Participants were allocated to placebo without therapy (n = 257), placebo with therapy (n = 256), supplements without therapy (n = 256), and supplements with therapy (n = 256). Main Outcome and Measures: Cumulative 1-year onset of MDD via the Mini International Neuropsychiatric Interview at 3, 6, and 12 months. Logistic regression using effect-coded variables (-1 indicating control, 1 indicating intervention) evaluated intervention effects both individually and in combination (interaction) on MDD onset. Results: Among 1025 participants (mean age, 46.5 years; 772 women [75%]; mean BMI, 31.4), 779 (76%) completed the trial. During the 12-month follow-up, 105 (10%) developed MDD: 25 (9.7%) patients in the placebo without therapy, 26 (10.2%) in the placebo with therapy, 32 (12.5%) in the supplement without therapy, and 22 (8.6%) in the supplement with therapy group. None of the treatment strategies affected MDD onset. The odds ratio (OR) for supplements was 1.06 (95% CI, 0.87-1.29); for therapy, 0.93 (95% CI, 0.76-1.13); and for their combination, 0.93 (95% CI, 0.76-1.14; P for interaction, .48). One person in the supplementation with therapy group, died. Twenty-four patients in each of the placebo groups and 24 patients in the supplementation with therapy group were hospitalized, and 26 patients in the supplementation-only group were hospitalized. Conclusions and Relevance: Among overweight or obese adults with subsyndromal depressive symptoms, multinutrient supplementation compared with placebo and food-related behavioral activation therapy compared with no therapy did not reduce episodes of major depressive disorder during 1 year. These findings do not support the use of these interventions for prevention of major depressive disorder. Trial registration: ClinicalTrials.gov Identifier: NCT02529423.
Authors: Margaret Rayman; Alexander Thompson; Margaret Warren-Perry; Rachel Galassini; Janet Catterick; Emma Hall; David Lawrence; Judith Bliss Journal: Biol Psychiatry Date: 2005-09-21 Impact factor: 13.382
Authors: Peter J Rogers; Katherine M Appleton; David Kessler; Tim J Peters; David Gunnell; Robert C Hayward; Susan V Heatherley; Leonie M Christian; Sarah A McNaughton; Andy R Ness Journal: Br J Nutr Date: 2007-10-24 Impact factor: 3.718
Authors: Andrew H Ford; Leon Flicker; Jenny Thomas; Paul Norman; Konrad Jamrozik; Osvaldo P Almeida Journal: J Clin Psychiatry Date: 2008-08 Impact factor: 4.384
Authors: Kaiping Burrows; Jennifer L Stewart; Chase Antonacci; Rayus Kuplicki; Katie Thompson; Ashlee Taylor; T Kent Teague; Martin P Paulus Journal: J Affect Disord Date: 2019-12-02 Impact factor: 4.839
Authors: Olivia I Okereke; Charles F Reynolds; David Mischoulon; Grace Chang; Chirag M Vyas; Nancy R Cook; Alison Weinberg; Vadim Bubes; Trisha Copeland; Georgina Friedenberg; I-Min Lee; Julie E Buring; JoAnn E Manson Journal: JAMA Date: 2020-08-04 Impact factor: 56.272
Authors: Joseph Firth; Scott B Teasdale; Kelly Allott; Dan Siskind; Wolfgang Marx; Jack Cotter; Nicola Veronese; Felipe Schuch; Lee Smith; Marco Solmi; André F Carvalho; Davy Vancampfort; Michael Berk; Brendon Stubbs; Jerome Sarris Journal: World Psychiatry Date: 2019-10 Impact factor: 49.548
Authors: Joseph Firth; Marco Solmi; Robyn E Wootton; Davy Vancampfort; Felipe B Schuch; Erin Hoare; Simon Gilbody; John Torous; Scott B Teasdale; Sarah E Jackson; Lee Smith; Melissa Eaton; Felice N Jacka; Nicola Veronese; Wolfgang Marx; Garcia Ashdown-Franks; Dan Siskind; Jerome Sarris; Simon Rosenbaum; André F Carvalho; Brendon Stubbs Journal: World Psychiatry Date: 2020-10 Impact factor: 49.548
Authors: Wolfgang Marx; Melissa Lane; Meghan Hockey; Hajara Aslam; Michael Berk; Ken Walder; Alessandra Borsini; Joseph Firth; Carmine M Pariante; Kirsten Berding; John F Cryan; Gerard Clarke; Jeffrey M Craig; Kuan-Pin Su; David Mischoulon; Fernando Gomez-Pinilla; Jane A Foster; Patrice D Cani; Sandrine Thuret; Heidi M Staudacher; Almudena Sánchez-Villegas; Husnain Arshad; Tasnime Akbaraly; Adrienne O'Neil; Toby Segasby; Felice N Jacka Journal: Mol Psychiatry Date: 2020-11-03 Impact factor: 15.992
Authors: Karmel W Choi; Murray B Stein; Kristen M Nishimi; Tian Ge; Jonathan R I Coleman; Chia-Yen Chen; Andrew Ratanatharathorn; Amanda B Zheutlin; Erin C Dunn; Gerome Breen; Karestan C Koenen; Jordan W Smoller Journal: Am J Psychiatry Date: 2020-08-14 Impact factor: 19.242